Therefore, clinical testing of CYP2C19 genotype can be used to assess the incidence of clopidogrel resistance risks, which can inform the treatment plan of clinical anti-platelet aggregation for the secondary prevention of stroke. This evidence concerns the gene CYP2C19 and Stroke.